close
Add to watchlist
CEL-SCI Corp (CVM) Healthcare, Biotechnology & Drugs
CEL-SCI Corporation engages in the research and development of drugs and vaccines used in the treatment of cancer. The company's lead product includes Multikine, which is under development for the treatment of cancer and is cleared for a Phase III clinical trial in advanced primary head and neck cancer patients. Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines, and colony-stimulating factors. The company also develops CEL-1000, which is derived from a pre-clinical technology called ‘Ligand Epitope Antigen Presentation System’ for protection for animals against avian flu, herpes, malaria, viral encephalitis, smallpox, vaccinia, and cancer, as well as CEL-2000, for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is based in Vienna, Virginia.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.42 |
| Volume | (mio) 3.17 |
| Volume Avg | (mio) 1.73 |
| 52 Week High | 0.74 |
| 52 Week Low | 0.27 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.14 |
| EPS change Q/Q | -25% |
| EPS change Q/Q Yr ago | 1000% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -112.5% |
| REV change Q/Q | 600% |
| REV change Q/Q Yr ago | -100% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |